Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long-Term Treatment With rhIGF-1 in GHIS

This study is ongoing, but not recruiting participants.
University of Oklahoma
Information provided by (Responsible Party):
Ipsen Identifier:
First received: December 10, 2007
Last updated: November 3, 2014
Last verified: November 2014

Long term study of the effects of dosing with rhIGF-1 on growth

Condition Intervention Phase
Growth Hormone Insensitivity Syndrome
Drug: mecasermin
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of the Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) Treatment in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Change in height [ Time Frame: duration of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • safety [ Time Frame: duration of study ] [ Designated as safety issue: Yes ]

Enrollment: 92
Study Start Date: January 1990
Estimated Study Completion Date: December 2015
Primary Completion Date: October 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mecasermin, injections BID of rhIGF-1 Drug: mecasermin
injections BID of rhIGF-1, mecasermin
Other Name: Increlex


Ages Eligible for Study:   2 Years to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Height <-2SD for age and gender
  • IGF-1 <-2SD for age and gender
  • Evidence of GH resistance

Exclusion Criteria:

  • closed epiphyses
  • prior active malignancy
  • major organ disfunction
  • treatment with medications that would diminish growth
  • clinically significant cardiac abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00571727

United States, California
Brisbane, California, United States, 94005
Sponsors and Collaborators
University of Oklahoma
Principal Investigator: Steven Chernausek, MD University of Oklahoma
  More Information

Responsible Party: Ipsen Identifier: NCT00571727     History of Changes
Other Study ID Numbers: Study 1419
Study First Received: December 10, 2007
Last Updated: November 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Ipsen:
insulin like growth factor
Larons syndrome

Additional relevant MeSH terms:
Laron Syndrome
Bone Diseases
Bone Diseases, Developmental
Endocrine System Diseases
Genetic Diseases, Inborn
Musculoskeletal Diseases
Pathologic Processes
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on November 19, 2014